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Septins are small GTPases that play a role in several important cellular processes. In
this review, we focus on the roles of septins in protein stabilization. Septins may regulate
protein stability by: (1) interacting with proteins involved in degradation pathways, (2)
regulating the interaction between transmembrane proteins and cytoskeletal proteins,
(3) affecting the mobility of transmembrane proteins in lipid bilayers, and (4) modulating
the interaction of proteins with their adaptor or signaling proteins. In this context,
we discuss the role of septins in protecting four different proteins from degradation.
First we consider botulinum neurotoxin serotype A (BoNT/A) and the contribution of
septins to its extraordinarily long intracellular persistence. Next, we discuss the role
of septins in stabilizing the receptor tyrosine kinases EGFR and ErbB2. Finally, we
consider the contribution of septins in protecting hypoxia-inducible factor 1α (HIF-1α)
from degradation.
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INTRODUCTION
Protein turnover is regulated by intracellular degradation pathways, including the ubiquitin-
proteasome and lysosome-autophagy systems. Protein ubiquitylation plays a key role in the
regulation of protein degradation. It is well-established that polyubiquitin chains, predominantly
but not exclusively with Lys48 linkages, target proteins to proteasomal degradation (Peng et al.,
2003; Xu et al., 2009; Kaiser et al., 2011; Kim et al., 2011). Ubiquitylation also acts as a signal
to endocytosis (Terrell et al., 1998; Mukhopadhyay and Riezman, 2007) or protein sorting of
internalized proteins to multi-vesicular bodies followed by lysosomal degradation (Raiborg and
Stenmark, 2009; Ren and Hurley, 2010; Stringer and Piper, 2011). In addition, ubiquitylation
regulates signaling by modulating protein-protein interactions (Mukhopadhyay and Riezman,
2007; Yau and Rape, 2016), which may affect localization of the protein and hence its susceptibility
to degradation.
The half-life of most cellular proteins is typically a few days (∼40–69 h) (Varshavsky, 1996).
Soluble proteins usually have a relatively short half-life (several hours), while transmembrane
proteins tend to survive longer (2–3 days). At the extremes, some proteins, like hypoxia-inducible
factor 1α (HIF-1α), last only seconds (Yu et al., 1998), while others, like the light chain of serotype
A botulinum neurotoxin, remain intact for several months (Dolly and Aoki, 2006).
Septins are small GTPases that form hetero-oligomeric structures and act as linkers between the
plasma membrane and the intracellular cytoskeleton. Through interactions with transmembrane
and cytosolic proteins, septins organize segregated membrane microdomains, and membrane-
associated protein complexes. The contribution of septins to the regulation of numerous
cellular processes, including cell division, protein trafficking, exocytosis, cell migration, and cell
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proliferation, has been described in several excellent reviews (Hall
and Russell, 2012; Mostowy and Cossart, 2012; Dolat et al., 2014;
Fung et al., 2014). In this review, we will focus on the roles of
septins in the regulation of protein stability.
Septins regulate protein stability by affecting several
intracellular processes. First, they interact with components of
endocytosis and exocytosis machinery (Beites et al., 1999, 2005;
Amin et al., 2008; Maimaitiyiming et al., 2013; Phan et al., 2013;
Tokhtaeva et al., 2015; Song et al., 2016). Second, they may
regulate the interaction between transmembrane proteins and
cytoskeletal proteins (Gilden and Krummel, 2010; Hagiwara
et al., 2011; Hall and Russell, 2012; Mostowy and Cossart,
2012; Bridges et al., 2016). Third, by forming diffusion barriers,
septins can modulate the mobility of transmembrane proteins
in lipid bilayers (Hagiwara et al., 2011; Saarikangas and Barral,
2011; Hall and Russell, 2012; Mostowy and Cossart, 2012; Fung
et al., 2014; Bridges et al., 2016). Fourth, septins form scaffolds
and thus can modulate the interaction of proteins with their
adaptor or signaling proteins (Ihara et al., 2007; Spiliotis and
Gladfelter, 2011; Ageta-Ishihara et al., 2013; Ghossoub et al.,
2013). All these processes can affect trafficking and sorting of
proteins to degradative pathways. Finally, septins interact with
proteins involved in degradation pathways, including ubiquitin
ligases, and de-ubiquitylating enzymes, thus modulating protein
turnover rate (Nakahira et al., 2010; Diesenberg et al., 2015;
Marcus et al., 2016).
SEPTINS CONTRIBUTE TO THE
REMARKABLE STABILITY OF BOTULINUM
NEUROTOXIN A LIGHT CHAIN
Botulinum Neurotoxins and Their Stability
Botulism is a life-threatening illness caused by neurotoxins
produced by Clostridium botulinum. Botulinum neurotoxins
(BoNTs) are synthesized as a single-chain 150 kDa polypeptide
that is later cleaved by proteases for biological activity into heavy
(100 kDa) and light (50 kDa) chains. BoNTs bind through the
heavy chain to specific receptors on motor neurons followed
by receptor-mediated endocytosis and translocation of their
light chains into the cytoplasm (Montal, 2010). Once inside the
neuron, the light chain acts as a zinc-dependent endoprotease
to cleave one of the SNARE (Soluble N-ethylmaleimide-sensitive
factor Attachment Protein REceptor) proteins involved in
vesicle-membrane fusion. This prevents release of acetylcholine
into the synaptic cleft, resulting in neuromuscular paralysis
(Dolly and Aoki, 2006; Popoff and Bouvet, 2009; Montal,
2010). As a result, patients with botulism develop severe muscle
weakness. The illness may progress to total loss of muscle
function, inability to breathe, and death unless supportive care
is provided (Arnon et al., 2001).
Of the seven serotypes of BoNT (A–G), human botulism
is caused by serotypes A, B, E and rarely by F (Arnon et al.,
2001). BoNT/A intoxication lasts surprisingly long: even after
57 weeks following exposure to BoNT/A, humans may still
demonstrate 22% muscle paralysis (Eleopra et al., 1998). Current
treatment for adult botulism consists of supportive care and
passive immunization with heptavalent equine antitoxin (Centers
for Disease and Prevention, 2010). Antitoxin lowers death rates
and shortens duration of symptoms only if administered within
24 h of disease onset (Arnon et al., 2001; Sobel, 2005). However,
antitoxin does not enter neurons and does not reverse paralysis;
hence, there is no specific treatment that targets BoNT once it is
inside motor neurons.
While they cleave the same SNARE protein (SNAP-25),
BoNT/A causes much longer duration of paralysis than BoNT/E
(Keller et al., 1999; Adler et al., 2001; Bajohrs et al., 2004). In
cultured spinal cord neurons, the proteolytic activity of BoNT/A,
and BoNT/E persists for more than 80 days and <1 day,
respectively (Keller et al., 1999). When expressed in cultured
neuronal cells, the light chain of BoNT/A (LCA) survives
significantly longer than the light chain of BoNT/E (LCE) due to
less efficient degradation (Fernández-Salas et al., 2004; Tsai et al.,
2010; Vagin et al., 2014). However, LCA is cleaved by proteases
in vitro as efficiently as LCE (Gimenez and DasGupta, 1993;
Beecher and DasGupta, 1997; Prabakaran et al., 2001). Thus,
intrinsic resistance to intracellular proteases does not explain
LCA persistence.
Septins Protect Botulinum Toxin Light
Chain a from Intracellular Degradation
Even though LCA does not possess a transmembrane domain,
it is localized in clusters almost exclusively at the plasma
membrane (Vagin et al., 2014). In contrast, LCE remains
in the cytoplasm, where its half-life corresponds to that of
typical cytoplasmic proteins (Foran et al., 2003; Fernández-
Salas et al., 2004). A double mutation, L428A/L429A, in a
dileucine-containing motif (EFYKLL), which is present in LCA
but not in LCE, decreases association of LCA with the plasma
membrane (Fernández-Salas et al., 2004), prevents its clustered
distribution, and shortens the half-life of LCA in cultured
neuronal cells (Vagin et al., 2014) and shortens neuroparalytic
effects of BoNT/A in mice (Wang et al., 2011). Furthermore,
fusion of LCE with BoNT/A stabilizes LCE, while L428A/L429A
mutation in the LCA portion of this chimera reverts LCE
back into a short-lived protein (Wang et al., 2011). Mass
spectrometry analysis identified septins as proteins that interact
with LCA but not with the L428A/L429A LCA mutant (Table 1)
(Vagin et al., 2014). Septins co-localize with LCA in plasma
membrane-associated clusters, and the L428A/L429A mutation
decreases this co-localization and accelerates ubiquitylation-
dependent degradation of LCA (Vagin et al., 2014). Similarly,
impairment of septin oligomerization with forchlorfenuron
(FCF), decreases LCA clustering, and increases LCA degradation
(Vagin et al., 2014). Therefore, the dileucine-mediated formation
of membrane-attached LCA- and septin-containing complexes
is crucial for the long-lasting stabilization of LCA and LCA-
related neuroparalytic activity. The involvement of septins in
LCA stabilization is consistent with the reports on enrichment
of septins in the presynaptic sites in neurons (Kinoshita et al.,
2000; Xue et al., 2004; Yang et al., 2010; Tsang et al., 2011) and
interaction of septins with SNARE proteins (Beites et al., 1999;
Dent et al., 2002; Ihara et al., 2007; Ito et al., 2009; Wasik et al.,
2012; Tokhtaeva et al., 2015).
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TABLE 1 | Septin-mediated regulation of protein stability.
Septin- regulated
protein
Septin(s)
involved in
regulation
Protein-septin interaction Effect(s) of septins on protein
stability
Molecular mechanism of
septin-mediated effect
References
LCA Septin 2
Septin 3
Septin 5
Septin 6
Septin 7
Septin 9
Septin 11
Dileucine motif (428L/429L)
required for binding
Protect from
ubiquitylation-dependent
degradation
Unknown Vagin et al., 2014
EGFR Septin 9
Septin 2
Septin 7
Not demonstrated Protects from ubiquitylation and
degradation
Septin 9 competes with
CBL for binding to CIN85
Diesenberg et al., 2015
ErbB2 Septin 2
Septin 9
Septin 7
Multiprotein complex with
several septins
Protect from ubiquitylation and
lysosomal degradation
Unknown Marcus et al., 2016
HIF-1α Septin 9 GTPase domain of septin 9
required for interaction
Protects from ubiquitylation and
degradation
Septin 9 competes for
RACK1 binding to HIF-1α
Amir et al., 2006, 2009;
Golan and Mabjeesh, 2013;
Vardi-Oknin et al., 2013
MET Septin 2
Septin 11
Unknown Differently modulate surface
expression and association with
the cytoskeleton
Unknown Mostowy et al., 2011
JNK Septin 9 GTPase domain of septin 9
required for interaction
Protects from degradation Unknown Gonzalez et al., 2009
SEPTINS STABILIZE RECEPTOR
TYROSINE KINASES
Persistent Signaling of Receptor Tyrosine
Kinases
EGFR family receptor tyrosine kinases (ErbB1 or EGFR, ErbB2,
ErbB3, ErbB4) trigger signaling cascades that regulate critical
cellular processes, such as growth, differentiation, proliferation,
adhesion, survival, and migration (Blume-Jensen and Hunter,
2001). One of the primary mechanisms that regulates the
duration of downstream signaling after activation is the removal
of these receptors from themembrane by endocytosis followed by
trafficking back to the cell surface or to lysosomes for degradation
(Wiley and Burke, 2001; Sorkin and Goh, 2009). Over-expression
and aberrant degradation of ErbB receptors lead to enhanced
or continuous signaling, promoting malignant transformation
(Sangwan and Park, 2006; Lemmon and Schlessinger, 2010;
Tebbutt et al., 2013; Arteaga and Engelman, 2014).
Endocytosis and degradative sorting of EGFR are regulated
by the ubiquitin ligase CBL (Levkowitz et al., 1996; Schmidt
and Dikic, 2005). EGFR stimulation by ligand binding triggers
the recruitment of CBL, which induces multi-mono- and K63-
polyubiquitylation of the receptor (Mosesson et al., 2003;
Huang et al., 2006, 2013). Whether ubiquitylation is required
for endocytosis is still a point of controversy. However, it
is generally agreed that CBL-mediated receptor ubiquitylation
targets internalized receptors for lysosomal degradation, while
non-ubiquitylated receptors are recycled back to the membrane.
CBL-interacting protein of 85 kDa (CIN85) mediates the
interaction between CBL and EGFR and hence is involved in the
downregulation of EGFR (Soubeyran et al., 2002; Haglund et al.,
2003).
In contrast to EGFR, ErbB2 does not have a known ligand
(Garrett et al., 2003) and is thought to be resistant to endocytic
down-regulation (Wang et al., 1999; Haslekås et al., 2005;
Roepstorff et al., 2008; Sorkin and Goh, 2008). Ubiquitylation is
important for ErbB2 degradation (Vuong et al., 2013), but the
involvement of CBL is not clear (Levkowitz et al., 1996; Klapper
et al., 2000). Heat shock protein 90 (HSP90) is required for stable
expression of ErbB2 at the plasma membrane, and disruption
of ErbB2 association with HSP90 allows for recruitment of
HSP70 and ubiquitin ligases CHIP and/or Cullin-5, leading to
ErbB2 ubiquitylation (Xu et al., 2002; Ehrlich et al., 2009),
internalization and lysosomal degradation (Tikhomirov and
Carpenter, 2000; Austin et al., 2004; Lerdrup et al., 2006).
Proteasomal activity is required for endocytosis and lysosomal
targeting of ErbB2 but is not directly involved in ErbB2
proteolysis (Lerdrup et al., 2006, 2007; Roepstorff et al., 2008).
Septins Protect Receptor Tyrosine Kinases
from Ubiquitylation, Endocytosis and
Degradation
CIN85 is involved in down-regulation of EGFR by tethering
CBL to the endocytic machinery in an EGF-dependent manner
(Dikic, 2002). A number of studies have suggested that CIN85
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participates in both the initial step of EGFR internalization
(Soubeyran et al., 2002) and also in receptor trafficking and
degradation (de Melker et al., 2001; Kowanetz et al., 2004;
Schroeder et al., 2012). Knockdown of CIN85 results in a
decrease in EGFR ubiquitylation (Rønning et al., 2011), while
prevention of CIN85 phosphorylation affects efficient sorting and
degradation of EGFR but has no effect on receptor endocytosis
(Schroeder et al., 2012). A recent study has identified CIN85 as an
interacting partner of septin 9 (Table 1) (Diesenberg et al., 2015).
This interaction depends on the presence of a conserved ProArg
motif in the N-terminus of septin 9 andmediates the formation of
a multiprotein complex of CIN85 with septin 9 and other septins.
In vitro binding studies suggest that septin 9 competes with
CBL for binding to CIN85 (Diesenberg et al., 2015). Stimulation
of EGFR with EGF in Hela cells results in the recruitment of
the CIN85-septin complex to the plasma membrane. Depletion
of septin 9 increases the degree of EGFR ubiquitylation and
accelerates its degradation. Taken together, these data suggest that
septin 9 negatively regulates EGFR degradation by preventing the
association of the ubiquitin ligase CBL with CIN85, resulting in
reduced EGFR ubiquitylation, and degradation (Diesenberg et al.,
2015).
Another recent study has identified septins as interacting
partners and regulators of the persistent expression of ErbB2
(Marcus et al., 2016). Several septins, including septin 2, septin
7, and septin 9, co-localize and interact with ErbB2 at the plasma
membrane in gastric cancer cells. Inhibition of septin filament
assembly-disassembly with FCF: (1) decreases association of
septins with ErbB2, (2) reduces plasma-membrane localization
of septins, (3) increases the amount of septin-free ErbB2, (4)
induces ubiquitylation of ErbB2, and (5) accelerates its lysosomal
degradation. A similar increase in ErbB2 degradation is observed
in septin 2-depleted cells. These results imply that normally
organized septin filaments protect ErbB2 from ubiquitylation,
endocytosis, and lysosomal degradation.
This protective effect of septins is not related to the regulation
of ErbB2 interaction with its chaperone HSP90 because the FCF-
induced ubiquitylation and degradation of ErbB2 is not altered
by geldanamycin (Marcus et al., 2016). This inhibitor down-
regulates ErbB2 by disrupting the ErbB2-HSP90 interaction
(Tikhomirov and Carpenter, 2000; Lerdrup et al., 2006, 2007).
Therefore, distinct and complementary effects of FCF, and
geldanamycin present a potential for augmented targeting of
ErbB2 persistence in cancer.
FCF-induced ubiquitylation of ErbB2 is unlikely to be due
to septin 9-mediated regulation of CBL as has been reported
for EGFR (Diesenberg et al., 2015), because ErbB2 does not
interact with CIN85 and FCF does not affect levels of EGFR
(Marcus et al., 2016). The involvement of other ubiquitin ligases
identified as septin interacting proteins (Nakahira et al., 2010;
Tokhtaeva et al., 2015) in septin-regulated ErbB2 ubiquitylation
has not been evaluated. Alternatively, septins may recruit de-
ubiquitylating enzymes to ErbB2, resulting in a lower steady state
level of ErbB2 ubiquitylation. In particular, ErbB2 interacts with a
de-ubiquitylating enzyme USP9x (Marx et al., 2010; Marcus et al.,
2016) that has been shown to protect ErbB2 from bortezomib-
induced lysosomal degradation (Marx et al., 2010). In addition,
septins play critical roles in endocytosis and exocytosis (Beites
et al., 1999, 2005; Maimaitiyiming et al., 2013; Phan et al., 2013;
Tokhtaeva et al., 2015; Song et al., 2016), and disruption of septin
dynamics with FCFmay induce ErbB2 internalization or delay its
recycling to the plasma membrane.
SEPTINS STABILIZE HYPOXIA-INDUCIBLE
FACTOR 1α
Role of HIF-1α in Cell Responses to
Hypoxia
HIF-1 is a transcription factor and key regulator of cellular
responses to changes in oxygen concentration that allow cell
adaptation and survival under hypoxic conditions (Semenza,
2014). HIF-1 is composed of the oxygen-regulated subunit,
HIF-1α, and the constitutively expressed HIF-1β subunit. HIF-
1α is constantly produced and degraded under normoxic
conditions due to oxygen-dependent hydroxylation, which
promotes binding of von Hippel-Lindau protein (VHL), leading
to ubiquitylation, and proteasomal degradation of HIF-1α. Under
hypoxic conditions, HIF-1α is not hydroxylated, does not interact
with VHL, translocates to the nucleus, and binds to hypoxia-
response elements in target genes. The expression of over 70
genes is known to be activated at the transcriptional level
by HIF-1 (Semenza, 2014). HIF-1α rapidly accumulates under
hypoxic conditions and is degraded upon reoxygenation with
a half-life of under 1 min (Yu et al., 1998). Another level
of post-translational regulation does not depend on oxygen,
hydroxylation, or VHL but requires the interaction between HIF-
1α and RACK1 (receptor of activated protein C kinase). RACK1
competes with HSP90 for binding to HIF-1α and promotes
the proteasome-dependent degradation of HIF-1α (Liu et al.,
2007; Liu and Semenza, 2007). Activation of the HIF system
has been observed in carcinogenesis and numerous cancers
(Semenza, 2012, 2016a,b; Hubbi and Semenza, 2015). Increased
levels of HIF-1 activity are often associated with increased tumor
aggressiveness, therapeutic resistance, and mortality.
Septin 9 Protects HIF-1α from Degradation
A search for HIF-1α-interacting proteins in human prostate
cancer cells identified septin 9 (Sept9_v1 isoform) (Amir et al.,
2006). Over-expression of septin 9 decreases ubiquitylation
and degradation of HIF-1α and activates HIF-1α-dependent
transcriptome (Amir et al., 2006). Co-immunoprecipitation
experiments show that septin 9 competes with RACK1 for
binding to HIF-1α (Amir et al., 2009). Inhibition of HSP90
induces RACK1-dependent HIF-1α degradation, and the rate of
this degradation is significantly lower in cells over-expressing
septin 9 (Amir et al., 2009). Taken together, these results implicate
septin 9 in oxygen-independent stabilization of HIF-1α. As
long as HIF-1α is bound to HSP90 or septin 9, it is protected
from RACK1-mediated degradation via the proteasome. In the
presence of HSP90 inhibitors, the HIF-1α-HSP90 association
is disrupted, leading to a competition between RACK1, which
promotes HIF-1α degradation, and septin 9, which confers
HIF-1α stabilization (Amir et al., 2009). In support of this
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HIF-1α-stabilizing role of septin 9, disruption of normal
assembly-disassembly of septin oligomers with FCF induces
degradation of HIF-1α, and inhibition in HIF-1α transcriptional
activity in various cancer cell types (Vardi-Oknin et al., 2013).
CONCLUDING REMARKS
Septins stabilize integral membrane proteins (EGFR and ErbB2),
membrane-associated proteins (LCA), and cytosolic/nuclear
proteins (HIF-1α) by attenuating their ubiquitylation and
degradation. Septin 9 also interacts with and stabilizes another
cytosolic/nuclear protein, c-Jun-N-terminal kinase (JNK)
(Gonzalez et al., 2009), but whether septin 9 affects the degree of
JNK ubiquitylation has not been investigated. Septin 2 and septin
11 regulate surface expression of MET receptor tyrosine kinase
by modulating its mobility in the lipid bilayer and its linkage to
the underlying cytoskeleton (Mostowy et al., 2011). However,
it is not clear if septins affect MET degradation. Only some of
the molecular events underlying the protective effects of septins
against protein ubiquitylation and degradation are understood
(Table 1), and further studies are required to determine the
detailed mechanisms of septin dependent protein stabilization.
Understanding the mechanism by which septins contribute to
intracellular stability of LCA would provide valuable insights for
treating BoNT intoxication. On the other hand, the remarkable
stability of LCA is fundamental in the success of BoNT/A for
long-term treatment of several disorders as well as cosmetic
therapies (Bhidayasiri and Truong, 2005; Chancellor et al., 2013;
Esquenazi et al., 2013; Hallett et al., 2013; Naumann et al., 2013;
Jost et al., 2015; Choi et al., 2016), and a super-stable LCA would
be useful therapeutically.
A better understanding of septin contribution to the
abnormal persistence of EGFR and ErbB2 in cancer cells will
provide a potential treatment target for aggressive malignancies.
Receptor-targeted therapies, such as monoclonal antibodies
(e.g., trastuzumab), and tyrosine kinase inhibitors (e.g.,
gefitinib), are effective against several types of malignancies,
but tumors may develop resistance to these agents due to
compensatory mechanisms (Hynes and Lane, 2005; Takeuchi
and Ito, 2011; Arteaga and Engelman, 2014), emphasizing
the evolving need to develop new synergistic treatment
strategies.
Knowledge of the pathways of septin contribution in oxygen-
independent stabilization of HIF-1α would provide a better
understanding of the reasons for HIF-1α over-expression in
various cancers even in aerobic conditions, which correlates with
poor prognosis, making HIF-1α an important target for cancer
therapy. A better understanding of septin-mediated stabilization
of HIF-1α opens the way to new therapeutic approaches to target
“normoxic” tumor cells (Semenza, 2012; Burroughs et al., 2013;
Warfel and El-Deiry, 2014).
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